

# Robert M Ward

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8224053/publications.pdf>

Version: 2024-02-01

31  
papers

687  
citations

623574

14  
h-index

552653

26  
g-index

31  
all docs

31  
docs citations

31  
times ranked

843  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a severity scale to assess chronic lung disease after extremely preterm birth. <i>Pediatric Pulmonology</i> , 2021, 56, 1583-1592.	1.0	3
2	Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 747-765.	1.5	1
3	QTc Intervals Are Prolonged in Late Preterm and Term Neonates during Therapeutic Hypothermia but Normalize Afterwards. <i>Children</i> , 2021, 8, 1153.	0.6	3
4	Dose-escalation trial of budesonide in surfactant for prevention of bronchopulmonary dysplasia in extremely low gestational age high-risk newborns (SASSIE). <i>Pediatric Research</i> , 2020, 88, 629-636.	1.1	21
5	Supportive care medications coinciding with chemotherapy among children with hematologic malignancy. <i>Leukemia and Lymphoma</i> , 2020, 61, 1920-1931.	0.6	4
6	Pediatric Age Groups and Approach to Studies. <i>Therapeutic Innovation and Regulatory Science</i> , 2019, 53, 584-589.	0.8	25
7	Pharmacometrics in Pediatrics. <i>Therapeutic Innovation and Regulatory Science</i> , 2019, 53, 579-583.	0.8	4
8	Principles of Pharmacokinetics in the Pregnant Woman and Fetus. <i>Clinics in Perinatology</i> , 2019, 46, 383-398.	0.8	14
9	Development of a neonatal adverse event severity scale through a Delphi consensus approach. <i>Archives of Disease in Childhood</i> , 2019, 104, 1167-1173.	1.0	40
10	The Need for Pediatric Drug Development. <i>Journal of Pediatrics</i> , 2018, 192, 13-21.	0.9	53
11	Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including) Tj ETQq1 1 0.784314 rgBT <sub>1</sub> /Overlook	1.1	77
12	Administration of Inhaled Pulmonary Vasodilators to the Mechanically Ventilated Neonatal Patient. <i>Paediatric Drugs</i> , 2017, 19, 183-192.	1.3	15
13	Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates. <i>BMC Pharmacology &amp; Toxicology</i> , 2016, 17, 22.	1.0	14
14	A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2016, 101, F236-F243.	1.4	32
15	Inositol Analysis by HPLC and Its Stability in Scavenged Sample Conditions. , 2015, 5, 077-80.		3
16	Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. <i>Pediatric Research</i> , 2015, 78, 315-322.	1.1	42
17	Neonatal Medications. <i>Pediatric Clinics of North America</i> , 2015, 62, 525-544.	0.9	4
18	Ethics of Drug Studies in the Newborn. <i>Paediatric Drugs</i> , 2015, 17, 37-42.	1.3	13

#	ARTICLE	IF	CITATIONS
19	Population Pharmacokinetics of Darbepoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1237-1244.	1.6	7
20	Applying Regulatory Science to Develop Safe and Effective Medicines for Neonates: Report of the US Food and Drug Administration First Annual Neonatal Scientific Workshop, October 28-29, 2014. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 623-631.	0.8	9
21	Commentary. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 606-607.	1.1	9
22	The pharmacokinetics of methadone and its metabolites in neonates, infants, and children. <i>Paediatric Anaesthesia</i> , 2014, 24, 591-601.	0.6	67
23	Pharmacokinetics and safety of a single intravenous dose of myo-inositol in preterm infants of 23-29 wk. <i>Pediatric Research</i> , 2013, 74, 721-729.	1.1	21
24	Regulation of CYP3A genes by glucocorticoids in human lung cells. <i>F1000Research</i> , 2013, 2, 173.	0.8	4
25	Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 555-561.	0.8	55
26	Criteria supporting the study of drugs in the newborn. <i>Clinical Therapeutics</i> , 2006, 28, 1385-1398.	1.1	25
27	Drug Disposition in the Late Preterm (‘‘Near-Term’’) Newborn. <i>Seminars in Perinatology</i> , 2006, 30, 48-51.	1.1	12
28	Albuterol delivery in a neonatal ventilated lung model: Nebulization versus chlorofluorocarbon- and hydrofluoroalkane-pressurized metered dose inhalers. <i>Pediatric Pulmonology</i> , 2001, 31, 247-254.	1.0	12
29	Preaxial ray reduction defects as part of valproic acid embryofetopathy. <i>Prenatal Diagnosis</i> , 1993, 13, 909-918.	1.1	60
30	Drug Therapy of the Fetus. <i>Journal of Clinical Pharmacology</i> , 1993, 33, 780-789.	1.0	34
31	History of Children and the Development of Regulations at the FDA. , 0, , 6-15.		4